TY  - BOOK
AU  - Alex,Alexander A.
AU  - Harris,C.John
AU  - Smith,Dennis A.
TI  - Attrition in the pharmaceutical industry: reasons, implications, and pathways forward 
SN  - 9781118914342 (epub)
AV  - HD9665.5 
U1  - 615.1068/5 23
PY  - 2015///
CY  - Hoboken, New Jersey
PB  - John Wiley & Sons
KW  - Pharmaceutical industry
KW  - Management
KW  - Capital productivity
KW  - Industrial efficiency
KW  - Drug development
KW  - fast
KW  - MEDICAL / Pharmacology
KW  - bisacsh
KW  - Electronic books
N1  - Includes index; Attrition in drug discovery and development / Scott Boyer, Clive Brealey and Andrew M. Davis -- Compound attrition at the pre-clinical phase / Cornelis E.C.A. Hop -- Attrition in phase I / Dennis A. Smith and Thomas A. Baillie -- Compound attrition in phase II/III / Alexander Alex, C. John Harris, Wilma W. Keighley and Dennis A. Smith -- Post-marketing attrition / Dennis A. Smith -- Influence of the regulatory environment on attrition / Robert T. Clay -- Experimental screening strategies to reduce attrition risk / Marie-Claire Peakman, Matthew Troutman, Rose Gonzales and Anne Schmidt -- Medicinal chemistry strategies to prevent compound attrition / J. Richard Morphy -- Influence of phenotypic and target-based screening strategies on compound attrition and project choice / Andrew Bell, Wolfgang Fecke and Christine Williams -- In silico approaches to address compound attrition / Peter Gedeck, Christian Kramer, Richard Lewis -- Current and future strategies for improving drug discovery efficiency / Peter Mbugua Njogu and Kelly Chibale -- Impact of investment strategies, organizational structure and corporate environment on attrition, and future investment strategies to reduce attrition / Geoff Lawton; mkt
UR  - http://dx.doi.org/10.1002/9781118819586
ER  -